ArticleNature2022
Structure of the MRAS-SHOC2-PP1C phosphatase complex.
Open access · hybridAbstract read
In one paragraph
Article in Nature, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
3.9field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Pooled it
- Context-dependent synthetic lethality - an emerging precision therapeutic approach.Nature reviews. Cancer · 2026Review
- Expression of LIFR in tumor and SHOC2, YAP1 in plasma mRNA as potential biomarkers in KRASScientific reports · 2026Article
- Combined Inhibition of HRAS and MEK Induces Tumor Regression and Restores Myogenic Differentiation in HRAS-Mutant Rhabdomyosarcoma.Cancer research · 2026Article
- Revisiting RAS family GTPase signaling: effector selectivity and oncogenic bypass.The Biochemical journal · 2026Review
- Analysis of the Modulation of RAF Signaling by 14-3-3 Proteins.Bulletin of mathematical biology · 2026Article
- Positive cooperativity between RAS-binding and cysteine-rich domains regulates RAF membrane binding kinetics via lateral rebinding.Nature communications · 2026Article
- Structure of SHOC2-KRAS-PP1C complex reveals RAS isoform-specific determinants and insights into targeting complex assembly by RAS inhibitors.Nature communications · 2026Article
- Phosphorylation Protects Oncogenic RAS from LZTR1-Mediated Degradation.bioRxiv : the preprint server for biology · 2026Article
- The CTLH ubiquitin ligase substrates ZMYND19 and MKLN1 negatively regulate mTORC1 at the lysosomal membrane.Nature communications · 2025Article
- Targeting Kinase Suppressor of Ras 1 (KSR1) for Cancer Therapy.Pharmaceutics · 2025Review
- An in vitro BRAF activation assay elucidates molecular mechanisms driving disassembly of the autoinhibited BRAF state.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Tumor heterogeneity underlies clinical outcome and MEK inhibitor response in somatic NF1-mutant glioblastoma.JCI insight · 2025Article
- Novel paradigms in KRAS targeting: Unveiling strategies to combat drug resistance.Chinese medical journal · 2025Review
- Small-molecule targeting BCAT1-mediated BCAA metabolism inhibits the activation of SHOC2-RAS-ERK to induce apoptosis of Triple-negative breast cancer cells.Journal of advanced research · 2025Article
- Cryo-EM structures of CRAF/MEK1/14-3-3 complexes in autoinhibited and open-monomer states reveal features of RAF regulation.Nature communications · 2025Article
- Article
- The small GTPase MRAS is a broken switch.Nature communications · 2025Article
- Targeting KAT7 inhibits the progression of colorectal cancer.Theranostics · 2025Article
- Protein serine/threonine phosphatases in tumor microenvironment: a vital player and a promising therapeutic target.Theranostics · 2025Review
Corrections and comments
- Commented on by
Authors and funding
24 authors at 4 institutions in 3 countries.
Zachary J Hauseman *Novartis Institutes for BioMedical Research, Cambridge, MA, USA. zachary.hauseman@novartis.com.ORCID http://orcid.org/0000-0002-0260-2326
Michelle Fodor *Novartis Institutes for BioMedical Research, Cambridge, MA, USA.
Anxhela DhembiNovartis Institutes for BioMedical Research, Cambridge, MA, USA.
Jessica ViscomiNovartis Institutes for BioMedical Research, Cambridge, MA, USA.
David EgliNovartis Institutes for BioMedical Research, Basel, Switzerland.
Melusine BleuNovartis Institutes for BioMedical Research, Basel, Switzerland.
Stephanie KatzNovartis Institutes for BioMedical Research, Basel, Switzerland.
Eunyoung ParkDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.
Dong Man JangDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0003-0701-0503
Kathryn A PorterNovartis Institutes for BioMedical Research, Cambridge, MA, USA.
Fabian MeiliNovartis Institutes for BioMedical Research, Cambridge, MA, USA.
Hongqiu GuoNovartis Institutes for BioMedical Research, Cambridge, MA, USA.
Grainne KerrNovartis Institutes for BioMedical Research, Basel, Switzerland.
Sandra MolléNovartis Institutes for BioMedical Research, Basel, Switzerland.
Camilo Velez-VegaNovartis Institutes for BioMedical Research, Cambridge, MA, USA.
Kim S BeyerNovartis Institutes for BioMedical Research, Basel, Switzerland.ORCID http://orcid.org/0000-0002-3047-304X
Giorgio G GalliNovartis Institutes for BioMedical Research, Basel, Switzerland.ORCID http://orcid.org/0000-0002-9401-060X
Saveur-Michel MairaNovartis Institutes for BioMedical Research, Basel, Switzerland.
Travis StamsNovartis Institutes for BioMedical Research, Cambridge, MA, USA.
Kirk ClarkNovartis Institutes for BioMedical Research, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-8424-4798
Michael J EckDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0003-4247-9403
Luca TordellaNovartis Institutes for BioMedical Research, Basel, Switzerland. luca.tordella@novartis.com.ORCID http://orcid.org/0000-0002-0542-7834
Claudio R ThomaNovartis Institutes for BioMedical Research, Cambridge, MA, USA. claudio.thoma@novartis.com.
Daniel A KingNovartis Institutes for BioMedical Research, Cambridge, MA, USA. dan.king@novartis.com.
Novartis (Switzerland) · CHNovartis (United States) · USHarvard University · USNovartis (China) · CN
Funding
Structural biology and drug discovery targeting oncogenic EGFR and BRAF kinasesR50CA221830 · NCI · DANA-FARBER CANCER INST · PI PARK, EUNYOUNG · 2017 to 2021
$942kNCI NIH HHS R50 CA221830
Abstract
RAS-MAPK signalling is fundamental for cell proliferation and is altered in most human cancers
Indexed as
Crystallography, X-RayIntracellular Signaling Peptides and ProteinsMultiprotein ComplexesProtein Phosphatase 1ras Proteins14-3-3 ProteinsGuanosine TriphosphateHumansMAP Kinase Signaling SystemMutationProtein IsoformsProtein Subunitsraf Kinases14-3-3 ProteinsGuanosine TriphosphateIntracellular Signaling Peptides and ProteinsMRAS protein, humanMultiprotein ComplexesProtein IsoformsProtein Phosphatase 1Protein Subunitsraf Kinasesras ProteinsSHOC2 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.